London – 18.06.2025 – Partners4Access (P4A), a global expert in market access for orphan drugs and advanced therapies, is proud to announce the launch of its new JCA & Market Expansion webpage. The digital platform is a direct outcome of insights and industry engagement gathered during the P4A Access Summit 2025: JCA & Market Expansion Unlocked, held in-person on May 13th in Zug, Switzerland.
Designed to equip pharmaceutical and biotech leaders with strategic tools and guidance, the new webpage explores the evolving landscape of the Joint Clinical Assessment (JCA) and broader European market expansion. It reflects on the key themes and actionable learnings from the Access Summit, which brought together senior stakeholders across rare diseases, cell and gene therapy, and market access. The insights, ideas and learnings have been condensed into a PDF report that you can download today.
With the EU’s upcoming JCA reforms set to redefine commercialization strategies, the Access Summit offered attendees a blend of hands-on workshops and expert-led discussions—focusing on PICO optimization, regulatory readiness under the EU Pharmaceutical Strategy, and the impact of launch conditionality on orphan drugs and ATMPs.
The morning JCA workshop delivered practical tools for upcoming submissions, while the afternoon sessions explored scalable pathways for global companies seeking European market entry. The event concluded with a networking reception that sparked valuable conversations and collaborations.
P4A extends its gratitude to all participants for their contributions in shaping a future where faster, equitable access to innovative therapies becomes a reality across Europe.
To explore the new JCA & Market Expansion webpage and access key takeaways from the Access Summit, visit https://partners4access.com/insights/p4a-access-summit-2025/
About Partners4Access
Partners4Access is a global leader in pharmaceutical innovation and orphan drug access. With a global presence, we are dedicated to supporting our clients and access to life-changing therapies to patients worldwide.
